Keywords: لیپوگلیکوپپتید; Telavancin; S. aureus; Lipoglycopeptide; Complicated skin and skin-structure infection;
مقالات ISI لیپوگلیکوپپتید (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: لیپوگلیکوپپتید; Osteomyelitis; Telavancin; Outpatient parenteral antimicrobial therapy; Lipoglycopeptide;
Keywords: لیپوگلیکوپپتید; Dalbavancina; Modelos animales; In vivo; Lipoglucopéptido; Dalbavancin; Animal models; In vivo; Lipoglycopeptide;
Keywords: لیپوگلیکوپپتید; Lipoglycopeptide; Children; MRSA;
Keywords: لیپوگلیکوپپتید; MRSA; ABSSSI; Lipoglycopeptide;
Keywords: لیپوگلیکوپپتید; Acute bacterial skin infection; Single-dose treatment; Clinical efficacy; MRSA; Lipoglycopeptide; Phase 3 study;
Keywords: لیپوگلیکوپپتید; Broth microdilution; Susceptibility; Lipoglycopeptide; Polysorbate-80;
Keywords: لیپوگلیکوپپتید; Tyrocidine A; Lipoglycopeptide; Solid-phase peptide synthesis; Macrocyclic peptide; Glycosylation;
Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014
Keywords: لیپوگلیکوپپتید; Oritavancin; Lipoglycopeptide; Gram-positive cocci;
Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by Staphylococcus aureus
Keywords: لیپوگلیکوپپتید; cost-effectiveness; hospital-acquired pneumonia; lipoglycopeptide; modeling; stewardship; telavancin;
Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen
Keywords: لیپوگلیکوپپتید; CLABSI; Cross-resistance; Glycopeptide resistance; Lipoglycopeptide; Dalbavancin;
Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents
Keywords: لیپوگلیکوپپتید; Teicoplanin; Lipoglycopeptide; Maleimide; Sulfonamide; Influenza virus inhibitor; Coronavirus; DCM; dichloromethane; DMF; dimethylformamide; CPE; cytopathic effect; Et3N; triethylamine; Galp; galactopyranose; HA; hemagglutinin; HIV; human immunodeficiency
Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents
Keywords: لیپوگلیکوپپتید; Bactericidal; Lipoglycopeptide; Acute bacterial skin and skin-structure infection; ABSSSI;
In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci
Keywords: لیپوگلیکوپپتید; Lipoglycopeptide; Enterococci; Susceptibility;
Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014)
Keywords: لیپوگلیکوپپتید; Broth microdilution; Susceptibility; Surveillance; Lipoglycopeptide;
Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013)
Keywords: لیپوگلیکوپپتید; Broth microdilution; Susceptibility; Lipoglycopeptide; Polysorbate 80;
In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014
Keywords: لیپوگلیکوپپتید; Skin and soft-tissue infection; Surveillance; Lipoglycopeptide;
Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus
Keywords: لیپوگلیکوپپتید; Lipoglycopeptide; Inoculum effect; Resistance trends;
Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009)
Keywords: لیپوگلیکوپپتید; Telavancin; Lipoglycopeptide; Staphylococcus aureus; Gram-positive; USA;
Update on the telavancin activity tested against European staphylococcal clinical isolates (2009–2010)
Keywords: لیپوگلیکوپپتید; Telavancin; Lipoglycopeptide; Staphylococcus spp.; Glycopeptides; Europe
In vitro activity of oritavancin against community-associated meticillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA)
Keywords: لیپوگلیکوپپتید; Oritavancin; Lipoglycopeptide; MRSA
Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007–2008)
Keywords: لیپوگلیکوپپتید; Telavancin; Lipoglycopeptide; Staphylococcus spp.; Surveillance; Europe
Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results
Keywords: لیپوگلیکوپپتید; Telavancin; Staphylococcus aureus; Lipoglycopeptide; Gram-positive
Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus
Keywords: لیپوگلیکوپپتید; Lipoglycopeptide; Human serum albumin; Staphylococcus aureus
Time–kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes
Keywords: لیپوگلیکوپپتید; Lipoglycopeptide; Bactericidal; Resistance
Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions
Keywords: لیپوگلیکوپپتید; Dalbavancin; Synergy; Lipoglycopeptide; Interaction studies
Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004)
Keywords: لیپوگلیکوپپتید; Dalbavancin; Lipoglycopeptide; Surveillance; Resistance; SSTI; CR-BSI